Boehringer Ingelheim: Atrial Fibrillation trials

The registry lists 45 Atrial Fibrillation studies with Boehringer Ingelheim as lead sponsor. 0 are open to participants now and 44 have results posted.

Phase 2 3Phase 3 3Phase 4 3No phase 36(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study Based on Japanese Medical Records That Looks at Bleeding Events in People With Atrial Fibrillation and Coronary Artery Disease Who Start Taking Either Dabigatran, Rivaroxaban, or WarfarinCompletedNCT05051904Results posted
• ReAHEAD: A Study to Find Out Whether Education Improves Adherence to Dabigatran in People With Atrial Fibrillation Who Are Younger Than 75 YearsCompletedNCT04532528Results posted
• This Study Observes the Usage of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) in Elderly Patients With a Heart Rhythm Disorder in SpainCompletedNCT03993119Results posted
• This Study Observes the Use of New Oral Anticoagulants (NOACs) in Patients With a Heart Rhythm Disorder in SpainCompletedNCT03285373Results posted
• This Study Uses the SITS Registry to Find Out When Patients With a Heart Rhythm Disorder (Atrial Fibrillation) Start Treatment With Dabigatran After They Had a StrokeCompletedNCT03258645Results posted
• Medical Need of OAC ReversalCompletedNCT03254147Results posted
• Comparative Effectiveness and Safety Between Warfarin and DabigatranCompletedNCT03254134Results posted
• Patients' Assessment of Satisfaction for Stroke Prevention in Atrial FibrillationCompletedNCT03187197Results posted
• Japanese Pradaxa PMS, Long TermCompletedNCT03175198Results posted
• Health-related Quality of Life in Patients on AnticoagulantsCompletedNCT03134911Results posted
• The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database AnalysisCompletedNCT03026556Results posted
• Validation of Predictors of OAC Initiation Using EMR DataCompletedNCT03006341Results posted
• Treatment Pattern of Oral Anticoagulants (OAC) in JapanCompletedNCT02982863Results posted
• Patient Convenience Study- NIS RELATECompletedNCT02849509Results posted
• Treatment Convenience in Patients Treated With Dabigatran for Stroke Prophylaxis in Atrial Fibrillation (SPAF)CompletedNCT02839746Results posted
• Anticoagulants Comparative Benefit-risk Ratio in Real LifeCompletedNCT02785354Results posted
• Patient Convenience Study (RE-SONANCE)CompletedNCT02684981Results posted
• Length of Stay in NVAF Patients Hospitalized and Initiated With Dabigatran or Warfarin in JapanCompletedNCT02631057Results posted
• Patient Convenience StudyCompletedNCT02597920Results posted
• Evaluation the Effectiveness of the Risk Minimisation Activities in the Treatment of Stroke Prevention in Atrial FibrillationCompletedNCT02433366Results posted
• Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)CompletedNCT02348723Phase 4Results posted
• Drug Persistence/Adherence in Patients Treated With Dabigatran or VKA for Stroke Prevention in Non Valvular Atrial Fibrillation (SPAF)CompletedNCT02240667Results posted
• Evaluation of Potential Off-label Use of Dabigatran Etexilate in EuropeCompletedNCT02240654Results posted
• Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)CompletedNCT02164864Phase 3Results posted
• Management of Major Bleeding Events in Atrial Fibrillation Patients Using PradaxaCompletedNCT02149303Results posted
• Sequential Expansion of Comparative Effectiveness of AnticoagulantsCompletedNCT02081807Results posted
• The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare CoverageCompletedNCT02061748Results posted
• The Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-Valvular Atrial Fibrillation Population With DoD Healthcare CoverageCompletedNCT02043808Results posted
• Management of Gastrointestinal and Urogenital (GI/GU) Bleedings in Atrial Fibrillation Patients Using PradaxaCompletedNCT02022020Results posted
• Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal FunctionCompletedNCT01896297Phase 4Results posted
• Anticoagulant Utilization PatternCompletedNCT01847560Results posted
• Comparative Effectiveness of Oral AnticoagulantsCompletedNCT01847547Results posted
• SPARK: Safety Study of Pradaxa in Atrial Fibrillation Patients by Regulatory Requirement of KoreaCompletedNCT01774370Results posted
• Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal ImpairmentCompletedNCT01721837Results posted
• GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)CompletedNCT01671007Results posted
• A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial FibrillationCompletedNCT01493557Phase 4Results posted
• Post-Marketing Surveillance of Prazaxa® on the Long-term Use in Patients With Nonvalvular Atrial FibrillationCompletedNCT01491178Results posted
• GLORIA-AF Registry Program - Second and Third PhasesCompletedNCT01468701Results posted
• GLORIA-AF Registry Program (Phase I)CompletedNCT01428765Results posted
• PETRO Stroke Prevention in Patients With AF by Treatment With Dabigatran, With and Without Aspirin, Compared to WarfarinCompletedNCT01227629Phase 2Results posted
• A Dose Response Study of Dabigatran Etexilate(BIBR 1048) in Pharmacodynamics and Safety in Patients With Non-valvular Atrial Fibrillation in Comparison to WarfarinCompletedNCT01136408Phase 2Results posted
• RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY TrialCompletedNCT00808067Phase 3Results posted
• Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran EtexilateCompletedNCT00262600Phase 3Results posted
• Long-term, Open-label Follow-up Treatment of Patients With A-fib Who Have Been Previously Treated With BIBR 1048TerminatedNCT00157248Phase 2Results posted
• GLORIA-AF Registry Program (Phase II/III)CompletedNCT01937377